PARPA-293-004 (ClinicalTrials.gov Identifier: NCT06931626) is a Phase 1 clinical trial evaluating an investigational oral therapy—a next-generation oral PARP1-selective inhibitor designed to target DNA repair pathways—in adults with relapsed small cell lung cancer. The trial is part of a multicenter research effort.

“OSF HealthCare remains dedicated to advancing early-phase cancer research, particularly in challenging diseases like small cell lung cancer,” said Dr. Jun Zhang, Vice President of Oncology Research at OSF HealthCare Cancer Institute. “Participating in these trials allows us to provide eligible patients with relapsed small cell lung cancer the potential for early access to promising investigational treatments that could address unmet needs in this aggressive disease.”

The study includes evaluation of the investigational therapy both alone and in combination with another therapy, with all treatment approaches being studied for research purposes in accordance with the approved study protocol.

All clinical research conducted at OSF HealthCare undergoes rigorous review and ongoing oversight to help ensure patient safety and ethical conduct.

Patients interested in learning more about clinical research at OSF HealthCare are encouraged to speak with their care team, call (844) 673-4467 or email sfmc.clinicaltrials@osfhealthcare.org.